ALMIRALL: MENSAJES DE LA CONFERENCE CALL RDOS. 1T’22 (ANÁLISIS BANCO SABADELL)
De la conference call de Rdos. 1T’22 destacamos los siguientes mensajes: Hitos Astra Zéneca: Confirmó que en adelante veremos unos 2-3 M euros al trimestre (tras los 9 M euros registrados en 1T’22), en línea con 2021. Recordamos que ALM anunció en 4T’21 que quedan pendientes de cobro unos 50 M euros que se recibirán en los próximos años tras la venta de Eklira por parte de Astra Zéneca a Covis Pharma y que se irán devengando con el cumplimiento de milestones operativos en China. El impacto a nivel de cuenta de resultados será de unos 10 M euros/anuales (vs 6 M euros BS(e)).
Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.